BioTroy Therapeutics Jointly Approved for Key Research Project
2024-12-27
Cell: BioTroy discovered the first ligand of CD3 as target for cancer immunotherapy
2024-04-12
BioTroy was awarded the"2023 Top 15 Chinese Innovative and Emerging Pharmaceutical Enterprise"
2024-03-29
BioTroy obtained two important qualifications
2024-03-01
Cell Reports Medicine: BioTroy Therapeutics jointly published Galectin-8’s role in tumor immune evasion
2024-01-26
China's IND Approved! BioTroy Therapeutics' Globally Pioneering Anti-Tumor Drug Receives NMPA Approval to Enter Clinical Phase
2024-01-15
